Conversion of Der p 23, a New Major House Dust Mite Allergen, into a Hypoallergenic Vaccine
- 15 May 2014
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 192 (10) , 4867-4875
Abstract
Der p 23, a new, major house dust mite (HDM) allergen that is recognized by >70% of HDM-allergic patients, has high allergenic activity and, therefore, must be considered an important component for HDM-specific immunotherapy. We constructed and characterized a hypoallergenic Der p 23 vaccine for HDM immunotherapy. Three nonallergenic peptides from the C-terminal IgE epitope-containing part of Der p 23 (P4, P5) and P6, a mutant peptide containing serines instead of cysteines, were identified. Peptides were fused to the hepatitis B virus–derived PreS domain as recombinant fusion proteins (i.e., PreS-2XP4P5 and PreS-4XP6) that were expressed in Escherichia coli and purified to homogeneity. Compared with Der p 23, PreS-2XP4P5 and PreS-4XP6 showed no relevant IgE reactivity and exhibited considerably reduced allergenic activity in basophil activation tests using blood from HDM-allergic patients. Upon immunization of rabbits, only PreS-2XP4P5 induced high levels of Der p 23–specific IgG Abs that inhibited binding of patients’ IgE to Der p 23, comparable to IgG Abs induced with Der p 23, whereas Abs induced with PreS-4XP6 had only low blocking capacity. Additionally, IgG Abs induced with PreS-2XP4P5 inhibited Der p 23–induced basophil activation comparable to IgG Abs induced with Der p 23. Compared with Der p 23, PreS-2XP4P5 induced lower T cell proliferation but higher levels of the tolerogenic cytokine IL-10 and the Th1 cytokine IFN-γ in PBMCs from HDM-allergic patients, indicating an immunomodulatory capacity of the fusion protein. Therefore, PreS-2XP4P5 represents a promising candidate for immunotherapy of HDM-allergic patients.Keywords
This publication has 42 references indexed in Scilit:
- A hypoallergenic variant of Der p 1 as a candidate for mite allergy vaccinesJournal of Allergy and Clinical Immunology, 2009
- Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen‐specific immunotherapyClinical & Experimental Allergy, 2009
- Variability of IgE reactivity profiles among European mite allergic patientsEuropean Journal of Clinical Investigation, 2008
- Reduction of the in vivo allergenicity of Der p 2, the major house-dust mite allergen, by genetic engineeringMolecular Immunology, 2008
- Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccineVaccine, 2006
- Standard skin prick testing and sensitization to inhalant allergens across Europe – a survey from the GA2LEN network*Allergy, 2005
- Specific Immunotherapy in AsthmaAllergy and Asthma Proceedings, 1994
- Immune reactivity to Der p I and Der p II in house dust mite sensitive patients attending paediatric and adult allergy clinicsClinical & Experimental Allergy, 1994
- The Pre-S Region of Hepadnavirus Envelope Proteins1988
- Peptide and protein molecular weight determination by electrophoresis using a high-molarity tris buffer system without ureaAnalytical Biochemistry, 1986